Editorial: peristomal pyoderma gangrenosum-a challenge for patients, healthcare professionals and research

Affiliations

¹ Department of Gastroenterology, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK.
² Department of Gastroenterology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.

Editorial

Tristan Townsend et al. Aliment Pharmacol Ther. 2020 Jul.

. 2020 Jul;52(2):404-405.

doi: 10.1111/apt.15822.

¹ Department of Gastroenterology, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK.
² Department of Gastroenterology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.

No abstract available

Comment on

Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease.
Wang J, Prenner J, Wang W, Sakuraba A, Hyman N, Dalal S, Hurst R, Cohen RD, Umanskiy K, Shogan BD, Alpert L, Rubin DT, Colwell J, Pekow J. Wang J, et al. Aliment Pharmacol Ther. 2020 Jun;51(12):1365-1372. doi: 10.1111/apt.15766. Epub 2020 May 7. Aliment Pharmacol Ther. 2020. PMID: 32383278

1. Brooklyn T, Dunnill G, Probert C. Diagnosis and treatment of pyoderma gangrenosum. BMJ. 2006;333:181-184.
1. Afifi L, Sanchez IM, Wallace MM, et al. Diagnosis and management of peristomal pyoderma gangrenosum: a systematic review. J Am Acad Dermatol. 2018;78:1195-1204.e1.
1. Shabbir J, Britton DC. Stoma complications: a literature overview. Colorectal Dis. 2010;12:958-964.
1. Maverakis E, Ma C, Shinkai K, et al. Diagnostic criteria of ulcerative pyoderma gangrenosum: a Delphi consensus of international experts. JAMA Dermatol. 2018;154:461-466.
1. Wang J, Prenner J, Wang W, et al. Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020;51:1365-1372.